A review of existing and emerging digital technologies to combat the global trade in fake medicines

Expert Opinion on Drug Safety

Volumn 16, Issue 5, 2017, Pages 587-602

  Mackey, Tim K ^a,b,c   Nayyar, Gaurvika ^b  

^a University of California   (United States)

^b Global Health Policy Institute   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

anti counterfeit; counterfeit medicines; Fake medicines; falsified medicines; health technology; online pharmacies; substandard medicines; supply chain

Indexed keywords

COUNTERFEIT DRUG; DRUG;

CONSUMER; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; INFORMATION PROCESSING; MEDICAL INFORMATICS; RADIOFREQUENCY IDENTIFICATION; REVIEW; GLOBAL HEALTH; HUMAN; PROCEDURES; RADIO FREQUENCY IDENTIFICATION DEVICE; STANDARDS; SUPPLY AND DISTRIBUTION;

COUNTERFEIT DRUGS; GLOBAL HEALTH; HUMANS; MEDICAL INFORMATICS; PHARMACEUTICAL PREPARATIONS; RADIO FREQUENCY IDENTIFICATION DEVICE;

EID: 85018723102     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2017.1313227     Document Type: Review

References (143)

1. Mackey TK, Liang BA., The global counterfeit drug trade:patient safety and public health risks. J Pharm Sci. 2011 Nov;100(11):4571–4579.
2. Jack A., Counterfeit medicines. Bitter pills. BMJ:british medical journal. Br Med J Publishing Group. 2007 Dec 1;335(7630):1120–1121.
3. Growing threat from counterfeit medicines. Bull World Health Organ. 2010 Apr;88(4):247–248.
4. Attaran A, Barry D, Basheer S, et al. How to achieve international action on falsified and substandard medicines. Bmj. 2012;345:e7381.
5. Mackey TK. Global health diplomacy and the governance of counterfeit medicines:a mapping exercise of institutional approaches [Internet]. ghd-net.org. 2013 [cited 2013 Jul1]. Available from:http://www.ghd-net.org/sites/default/files/Global%20Health%20Diplomacy%20and%20the%20Governance%20of%20Counterfeit%20Medicines.pdf
6. Woo J, Wolfgang S, Batista H. The effect of globalization of drug manufacturing, production, and sourcing and challenges for american drug safety. Clin Pharmacol Ther. 2008 Mar 1;83(3):494–497.
7. El-Jardali F, Akl EA, Fadlallah R, et al. Interventions to combat or prevent drug counterfeiting:a systematic review. BMJ Open. British Med J Publishing Group. 2015;5(3):e006290–0.
8. New W, WHO board agrees to drop the word “Counterfeit” after 30 years [Internet]. ip-watch.org. 2017 [cited 2017 Jan30]. Available from:http://www.ip-watch.org/2017/01/30/board-agrees-drop-word-counterfeit-30-years/
9. Clark F, Rise in online pharmacies sees counterfeit drugs go global. The Lancet. Elsevier. 2015 Mar 10;386(10001):1327–1328.
10. WHO. Substandard, spurious, falsely labelled, falsified and counterfeit (SSFFC) medical products [Internet]. WHO World Health Organization. 2016. [[cited 2017 Jan1]]. Available from:http://www.who.int/mediacentre/factsheets/fs275/en/
11. Blackstone EA, Fuhr JP, Pociask S, The health and economic effects of counterfeit drugs. Am Health Drug Benefits. Engage Healthcare Communications, LLC. 2014 Jun;7(4):216–224.
12. IOM. Countering the problem of falsified and substandard drugs - institute of medicine [Internet]. iom.edu. 2013 [cited 2013 Feb25]. Available from:http://www.iom.edu/Reports/2013/Countering-the-Problem-of-Falsified-and-Substandard-Drugs.aspx•• This is a comprehensive report.
13. Kohler JC, Pavignani E, Michael M, et al. An examination of pharmaceutical systems in severely disrupted countries. BMC Int Health Hum Rights. 2012 Dec 6;12(1):34.
14. Delepierre A, Gayot A, Carpentier A. Update on counterfeit antibiotics worldwide; public health risks. Med Mal Infect. 2012 Jun;42(6):247–255.
15. Venhuis BJ, Keizers PHJ, Klausmann R, et al. Operation resistance:A snapshot of falsified antibiotics and biopharmaceutical injectables in Europe. Cohen PA, Venhuis BJ, Brandt SD, editors. Drug Test Anal. 2016 Mar;8(3–4):398–401.
16. Mackey TK, Liang BA. Improving global health governance to combat counterfeit medicines:a proposal for a UNODC-WHO-Interpol trilateral mechanism. BMC Med. 2013;11:233.
17. Hamilton WL, Doyle C, Halliwell-Ewen M, et al. Public health interventions to protect against falsified medicines:a systematic review of international, national and local policies. Health Policy Plan. 2016 Dec;31(1):1448–1466.•• A comprehensive review detailing various policy approaches to tackling fake medicines.
18. Dipika Bansal SMKGPT, Anti-counterfeit technologies:a pharmaceutical industry perspective. Sci Pharm. Österreichische Apotheker-Verlagsgesellschaft, m. b. H. 2013 Mar 1;81(1):1.
19. Amon JJ, Dangerous medicines:unproven AIDS cures and counterfeit antiretroviral drugs. Global Health. BioMed Central Ltd. 2008 Feb 27;4(1):5.
20. Newton PN, Green MD, Mildenhall DC, et al. Poor quality vital anti-malarials in Africa - an urgent neglected public health priority. Malar J. BioMed Central. 2011 Dec 13;10(1):352.
21. Nayyar GM, Breman JG, Newton PN, et al. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis. 2012 Jun;12(6):488–496.
22. Mackey TK, Liang BA, York P, et al. Counterfeit drug penetration into global legitimate medicine supply chains:a global assessment. Am J Trop Med Hyg. American Society of Tropical Medicine and Hygiene. 2015 Jun;92(6 Suppl):59–67.•• This report is the first to analyze data on counterfeit medicine penetrations in the global drug supply chain.
23. Nayyar GML, Attaran A, Clark JP, et al. Responding to the pandemic of falsified medicines. Am J Trop Med Hyg. American Society of Tropical Medicine and Hygiene. 2015 Jun;92(6 Suppl):113–118.
24. Nayyar GML, Breman JG, Herrington JE, The global pandemic of falsified medicines:laboratory and field innovations and policy perspectives. Am J Trop Med Hyg. American Society of Tropical Medicine and Hygiene. 2015 Jun;92(6 Suppl):2–7.
25. Wigand RT, Mande DM, Wood JD. Information management and tracking of drugs in supply chains within the pharmaceutical industry. Eighth International Conference on Information Technology:New Generations. 2011;500–507.
26. QuintilesIMS. Global medicines use in 2020:outlook and Implications. www.imshealth.com [Internet]. Nov 2015. Available from:http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/global-medicines-use-in-2020.
27. Masoumi AH, Yu M, Nagurney A. A supply chain generalized network oligopoly model for pharmaceuticals under brand differentiation and perishability. Trans Res Part E:Logis Trans Rev. 2012 Jul;48(4):762–780.
28. Taylor D. RFID in the pharmaceutical industry:addressing counterfeits with technology. J Med Syst. 2014 Nov;38(11):141.
29. Bailey W, Globalization of the Life Sciences Supply Chain. wwwpwccom [Internet]. January/February 2011. Available from:http://www.pwc.com/us/en/health-industries/assets/pdf/globalization-of-the-life-sciences-supply-chain.pdf
30. Tremblay M. Medicines counterfeiting is a complex problem:a review of key challenges across the supply chain. Curr Drug Saf. 2013 Feb;8(1):43–55.
31. ISMP. Gray market, black heart:pharmaceutical gray market finds a disturbing niche during the drug shortage crisis [Internet]. ismp.org. 2011 [cited 2011 Sep26]. Available from:http://www.ismp.org/Newsletters/acutecare/showarticle.asp?ID=3
32. Rosenthal ET, The “gray market” raises concerns about cost, safety, and ethics. JNCI J Natl Cancer Inst. Oxford University Press. 2012 Feb 8;104:168–170.
33. Hemalatha R, Rao AS. Electronic solutions for combating counterfeit drugs. J Pharm Bioallied Sci Medknow Publications. 2015 Jul;7(3):230–232.
34. Mackey TK, Cuomo R, Guerra C, et al. After counterfeit Avastin®–what have we learned and what can be done? Nat Rev Clin Oncol. 2015 May;12(5):302–308.
35. Cuomo RE, Mackey TK. An exploration of counterfeit medicine surveillance strategies guided by geospatial analysis:lessons learned from counterfeit Avastin detection in the US drug supply chain. BMJ Open. British Med J Publishing Group. 2014;4(12):e006657–7.
36. Cuomo RE, Mackey TK, Stigler P. The economics of counterfeit Avastin:a geospatial and statistical analysis of demographic correlates to FDA warning letters. Pharmacoepidemiol Drug Saf. 2015 Jul;24(7):748–756.
37. Kohler JC, Mackey TK, Ovtcharenko N. Why the MDGs need good governance in pharmaceutical systems to promote global health. BMC Public Health. BioMed Central Ltd. 2014;141:63.
38. Baghdadi-Sabeti G, Kohler JC, Wondemagegnehu E, Measuring transparency in the public pharmaceutical sector:assessment instrument [Internet]. apps.who.int. 2009 [cited 2013 Feb26]. Available from:http://apps.who.int/medicinedocs/documents/s16732e/s16732e.pdf
39. Mackey TK, Kohler JC, Savedoff WD, et al. The disease of corruption:views on how to fight corruption to advance 21(st) century global health goals. BMC Med Biomed Central. 2016 Sep 29;14(1):149.
40. Mackey TK, Liang BA. Combating healthcare corruption and fraud with improved global health governance. BMC Int Health Hum Rights. 2012;12(1):23.
41. Nsimba SED. Problems associated with substandard and counterfeit drugs in developing countries:a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy. East Afr J Public Health. 2008 Dec;5(3):205–210.
42. Wertheimer AI, Norris J, Safeguarding against substandard/counterfeit drugs:mitigating a macroeconomic pandemic. Res Social Adm Pharm. Elsevier. 2009 Mar;5(1):4–16.
43. Karunamoorthi K, The counterfeit anti-malarial is a crime against humanity:a systematic review of the scientific evidence. Malar J. BioMed Central Ltd. 2014 Jun 2;13(1):209.
44. Tabernero P, Fernández FM, Green M, et al. Mind the gaps–the epidemiology of poor-quality anti-malarials in the malarious world–analysis of the worldwide antimalarial resistance network database. Malar J. BioMed Central. 2014;131:139.
45. Kovacs S, Hawes SE, Maley SN, et al. Technologies for detecting falsified and substandard drugs in low and middle-income countries. Sullivan DJ, editor. Plos ONE. 2014 Mar 26;9(3):e90601.•• A comprehensive review of existing technologies to combat fake medicines that this study adds to.
46. Coustasse A, Arvidson C, Rutsohn P, Pharmaceutical counterfeiting and the RFID technology intervention. J Hosp Mark Public Relations. Taylor & Francis Group. 2010 Jul;20(2):100–115.
47. Mackey TK, Liang BA. Pharmaceutical digital marketing and governance:illicit actors and challenges to global patient safety and public health. Global Health. 2013 Oct 16;9(1):45.
48. Maxwell SRJ, Webb DJ. Internet pharmacy:a web of mistrust? Bjcp. 2008 Aug;66(2):196–198.
49. Montoya ID. The root cause of patient safety concerns in an Internet pharmacy. Expert Opin Drug Saf. 2008 Jul;7(4):337–341.
50. Liang BA, Mackey T. Searching for safety:addressing search engine, website, and provider accountability for illicit online drug sales. Am J Law Med. 2009;35(1):125–184.
51. Mackey TK, Nayyar G, Digital danger:a review of the global public health, patient safety and cybersecurity threats posed by illicit online pharmacies. Br Med Bull. Oxford University Press. 2016 Jun;118(1):110–126.•• Review article specifically outlines the unique challenges faced by illicit online pharmacies to drug safety.
52. Liang BA, Mackey T. Direct-to-consumer advertising with interactive internet media:global regulation and public health issues. Jama. 2011 Feb 23;305(8):824–825.
53. Mackey TK, Liang BA. Global reach of direct-to-consumer advertising using social media for illicit online drug sales. J Med Internet Res. 2013;15(5):e105.
54. Orizio G, Merla A, Schulz PJ, et al. Quality of online pharmacies and websites selling prescription drugs:a systematic review. J Med Internet Res. 2011;13(3):e74.
55. Ivanitskaya L, Brookins-Fisher J, O Boyle I, et al. Dirt cheap and without prescription:how susceptible are young US consumers to purchasing drugs from rogue internet pharmacies? J Med Internet Res. [Internet] 2010; 122. Available from:/pmc/articles/PMC2885783/?report=abstract
56. WHO. Safety and security on the Internet:challenges and advances in member states [Internet]. WHO. 2011 [cited 2013 Mar5]. Available from:http://www.who.int/goe/publications/goe_security_web.pdf
57. Fittler A, Bősze G, Botz L. Evaluating aspects of online medication safety in long-term follow-up of 136 Internet pharmacies:illegal rogue online pharmacies flourish and are long-lived. J Med Internet Res. 2013;15(9):e199.
58. Fadlallah R, El-Jardali F, Annan F, et al. Strategies and systems-level interventions to combat or prevent drug counterfeiting:a systematic review of evidence beyond effectiveness. Pharmaceut Med. Springer International Publishing. 2016;305:263–276.
59. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States:origins and prospects for reform. Jama. 2016 Aug 23;316(8):858–871.
60. Orizio G, Rubinelli S, Schulz PJ, et al. “Save 30% if you buy today.” Online pharmacies and the enhancement of peripheral thinking in consumers. Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):970–976.
61. Naughton B, Roberts L, Dopson S, et al. Effectiveness of medicines authentication technology to detect counterfeit, recalled and expired medicines:a two-stage quantitative secondary care study. BMJ Open. 2016 Dec 9;6(12):e013837.
62. Li L. Technology designed to combat fakes in the global supply chain. Bus Horiz. 2013 Mar;56(2):167–177.
63. pwc. Digitization in pharma:gaining an edge in operations [Internet]. strategyand.pwc.com. 2016 [cited 2017 Jan30]. Available from:http://www.strategyand.pwc.com/reports/digitization-in-pharma
64. International Telecommunication Union. Press Release:ITU releases 2016 ICT figures. [Internet]. 2016 [cited 2017 Jan30]. Available from:http://www.itu.int/en/mediacentre/pages/2016-PR30.aspx
65. Isah H. Information and communication technology in combating counterfeit drugs. arxiv.org [Internet]. 2012. Available from:https://arxiv.org/ftp/arxiv/papers/1211/1211.1242.pdf.
66. Ur Rehman S, Ur Rasool RU, Ayub MS, et al. Reliable identification of counterfeit medicine using camera equipped mobile phones. InHigh Capacity Optical Networks and Enabling Technologies (HONET), 2011 2011 Dec 19 (pp. 273–279). IEEE.
67. Deus L, Technological roles in combating drug diversion and counterfeiting. J Pharm Pract. Sage Publications. 2016 Jun 30;19(3):146–152.
68. Zedlmayer G, mPedigree:a collective impact case study [Internet]. ssir.org. 2011 [cited 2017 Jan1]. Available from:https://ssir.org/articles/entry/mpedigree_a_collective_impact_case_study
69. You M, Zhong J, Hong Y, et al. Inkjet printing of upconversion nanoparticles for anti-counterfeit applications. Nanoscale. Royal Soc Chem. 2015 Mar 14;7(10):4423–4431.
70. Isa NM, Saaidin S, Sulaiman NA, et al. Pharmaceutical product information based on Android platform. InElectrical, Electronics and System Engineering (ICEESE), 2014 International Conference on 2014 Dec 9 (pp. 66-70). IEEE.
71. Yu H, Le HM, Kaale E, et al. Characterization of drug authenticity using thin-layer chromatography imaging with a mobile phone. J Pharm Biomed Anal. 2016 Jun;5(125):85–93.
72. Yu H, Le H, Lumetta S, et al. Smartphone-based thin layer chromatography for the discrimination of falsified medicines. InSENSORS, 2016 IEEE 2016 Oct 30 (pp. 1–3). IEEE.
73. Jordan F, Kutter M. Identifying counterfeit medicines with industry-suitable technologies. Pharmaceutical Engineering, The Offical Magazine of ISPE. 2012 May;32(3).
74. Sinhal K. Soon, bar code & unique no. on pill strips to check fakes [Internet]. 2011 [cited 2017 Jan30]. Available from:http://timesofindia.indiatimes.com/india/Soon-bar-code-unique-no-on-pill-strips-to-check-fakes/articleshow/7529728.cms
75. NAFDAC Nigeria Mobile Authentication Service (MAS) requirements on anti-malarial & antibiotics [Internet]. pharmasecure.com. [cited 2017 Jan 30]. Available from:http://www.pharmasecure.com/NAFDAC%20Nigeria%20MAS%20Newsletter.pdf
76. Shuaib H. A national ICT architecture for combating the counterfeit drug trade. www.academia.edu [Internet]. 2013. Available from:http://s3.amazonaws.com/academia.edu.documents/31545476/Drug_anti-Counterfeit_Paper.pdf?AWSAccessKeyId=AKIAIWOWYYGZ2Y53UL3A&Expires=1490919434&Signature=7A8jNasDmFmZzluUKfIJmWBQBKU%3D&response-content-disposition=inline%3B%20filename%3DHaffiz_Shuaib_A_National_ICT_Architectur.pdf.
77. Ting SL, Kwok SK, Tsang AHC, et al. Critical elements and lessons learnt from the implementation of an RFID-enabled healthcare management system in a medical organization. J Med Syst. Springer US. 2011 Aug;35(4):657–669.
78. Huang GQ, Qin Z, Qu T, et al. RFID-enabled pharmaceutical regulatory traceability system. InRFID-Technology and Applications (RFID-TA), 2010 IEEE International Conference on 2010 Jun 17 (pp. 211–216). IEEE.
79. Hall C. Technology for combating counterfeit medicine. Pathog Glob Health. 2013 Nov 12;106(2):73–76.
80. Yao X, Du W, Zhou X, et al. Security and privacy for data mining of RFID-enabled product supply chains. InSAI Computing Conference (SAI), 2016 2016 Jul 13 (pp. 1037-1046). IEEE.
81. Ting SL, Kwok SK, Albert HT, et al. Enhancing the information transmission for pharmaceutical supply chain based on Radio Frequency Identification (RFID) and internet of things. InSupply Chain Management and Information Systems (SCMIS), 2010 8th International Conference on 2010 Oct 6 (pp. 1–5). IEEE.
82. Kaul SD, Awasthi AK, RFID authentication protocol to enhance patient medication safety. J Med Syst. Springer US. 2013 Dec;37(6):9979.
83. Schapranow MP, Nagora M, Zeier A. CoMoSeR:cost model for security-enhanced RFID-aided supply chains. InSoftware, Telecommunications and Computer Networks (SoftCOM), 2010 International Conference on 2010 Sep 23 (pp. 11–16). IEEE.
84. Choi JB, Rogers J, Jones EC. The impact of a shared pharmaceutical supply chain model on counterfeit drugs, diverted drugs, and drug shortages. InManagement of Engineering and Technology (PICMET), 2015 Portland International Conference on 2015 Aug 2 (pp. 1879–1889). IEEE.
85. Nilsson E, Nilsson B, Järpe E. A pharmaceutical anti-counterfeiting method using time controlled numeric tokens. InRFID-Technologies and Applications (RFID-TA), 2011 IEEE International Conference on 2011 Sep 15 (pp. 343–347). IEEE.
86. Alzahrani N, Bulusu N. Securing pharmaceutical and high-value products against tag reapplication attacks using NFC tags. InSmart Computing (SMARTCOMP), 2016 IEEE International Conference on 2016 May 18 (pp. 1–6). IEEE.
87. Yao X, Zhou X, Ma J. Object event visibility for anti-counterfeiting in RFID-enabled product supply chains. InScience and Information Conference (SAI), 2015 2015 Jul 28 (pp. 141–150). IEEE.
88. Carley LR, Colak G, Chomas L, et al. Technologies for secure RFID authentication of medicinal pills and capsules. InRFID Technology and Applications (RFID-TA), 2016 IEEE International Conference on 2016 Sep 21 (pp. 10–15). IEEE.
89. Kim H, Jeong H, Park H. A study on RFID/USN based e-pedigree system for cold chain management. InTechnology Management Conference (ITMC), 2012 IEEE International 2012 Jun 25 (pp. 137–143). IEEE.
90. Chen C, Zhang F, Barras J, et al. Authentication of medicines using nuclear quadrupole resonance spectroscopy. IEEE/ACM Trans Comput Biol Bioinform. 2016 May;13(3):417–430.
91. Rahman F, Ahamed SI. Looking for needles in a haystack:detecting counterfeits in large scale RFID systems using batch authentication protocol. InPervasive Computing and Communications Workshops (PERCOM Workshops), 2012 IEEE International Conference on 2012 Mar 19 (pp. 811–816). IEEE.
92. Schapranow M-P, Zeier A, Plattner H, et al. A formal model for enabling RFID in pharmaceutical supply chains. InSystem Sciences (HICSS), 2011 44th Hawaii International Conference on 2011 Jan 4 (pp. 1–10). IEEE.
93. Freifeld CC, Brownstein JS, Menone CM, et al. Digital drug safety surveillance:monitoring pharmaceutical products in twitter. Drug Saf. Springer International Publishing. 2014 Apr 29;37(5):343–350.
94. Salathé M, Bengtsson L, Bodnar TJ, et al. Digital Epidemiology. Bourne PE, editor. Plos Comp Biol. Public Library of Science. 2012 Jul 26;8(7):e1002616.
95. Hay SI, George DB, Moyes CL, et al. Big data opportunities for global infectious disease surveillance. Plos Med. Public Library of Science. 2013 Apr 2;10(4):e1001413.
96. Katsuki T, Mackey TK, Cuomo R. Establishing a link between prescription drug abuse and illicit online pharmacies:analysis of twitter data. J Med Internet Res. 2015;17(12):e280.
97. Kalyanam J, Katsuki T, R G Lanckriet G, et al. Exploring trends of nonmedical use of prescription drugs and polydrug abuse in the Twittersphere using unsupervised machine learning. Addict Behav. 2017 Feb;65:289–295.
98. Obermeyer Z, Emanuel EJ. Predicting the future — big data, machine learning, and clinical medicine. N Engl J Med. 2016 Sep 29;375(13):1216–1219.
99. Adrover C. Identifying adverse effects of HIV drug treatment and associated sentiments using twitter. JMIR Public Health Surveill. 2015;1(2):e7. JMIR Publications Inc., Toronto, Canada http://publichealthjmirorg/2015/2/e7/
100. O’Connor K, Pimpalkhute P, Nikfarjam A, et al. American Medical Informatics Association. Pharmacovigilance on twitter? Mining tweets for adverse drug reactions. AMIA Annu Symp Proc. 2014;2014:924–933.
101. Lopes TJS, Shoemaker JE, Matsuoka Y, et al. Frontiers. Identifying problematic drugs based on the characteristics of their targets. Front Pharmacol. 2015;6:186.
102. Zhao J, Henriksson A, Kvist M, et al. American Medical Informatics Association. Handling temporality of clinical events for drug safety surveillance. AMIA Annu Symp Proc. 2015;2015:1371–1380.
103. Isah H, Trundle P, Neagu D. Social media analysis for product safety using text mining and sentiment analysis. InComputational Intelligence (UKCI), 2014 14th UK Workshop on 2014 Sep 8 (pp. 1–7). IEEE.
104. Voss EA, Boyce RD, Ryan PB, et al. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform. 2016 Dec;16(66):72–81.
105. Wang G, Jung K, Winnenburg R, et al. A method for systematic discovery of adverse drug events from clinical notes. J Am Med Inform Assoc. Oxford University Press. 2015 Nov;22(6):1196–1204.
106. Li A, Guo X, Xie J, et al. Validation of biomarkers in cardiotoxicity induced by Periplocin on neonatal rat cardiomyocytes using UPLC-Q-TOF/MS combined with a support vector machine. J Pharm Biomed Anal. 2016 May;10(123):179–185.
107. Drew J, Moore T. Automatic identification of replicated criminal websites using combined clustering. InSecurity and Privacy Workshops (SPW), 2014 IEEE 2014 May 17 (pp. 116–123). IEEE.
108. Koepke J, Kaza S, Abbasi A. Exploratory experiments to identify fake websites by using features from the network stack. InIntelligence and Security Informatics (ISI), 2012 IEEE International Conference on 2012 Jun 11 (pp. 126–128). IEEE.
109. Mavlanova T, Benbunan-Fich R. What does your online pharmacy signal? a comparative analysis of website trust features. InSystem Sciences (HICSS), 2010 43rd Hawaii International Conference on 2010 Jan 5 (pp. 1–10). IEEE.
110. Corona I, Contini M, Ariu D, et al. PharmaGuard:automatic identification of illegal search-indexed online pharmacies. InCybernetics (CYBCONF), 2015 IEEE 2nd International Conference on 2015 Jun 24 (pp. 324–329). IEEE.
111. Abbasi A, Zahedi F, Kaza S. Detecting fake medical web sites using recursive trust labeling. ACM Trans Inf. 2012;30:1–36.
112. Der MF, Saul LK, Savage S, et al. Knock it off:profiling the online storefronts of counterfeit merchandise. the 20th ACM SIGKDD international conference. New York, USA:ACM; 2014. p. 10.
113. Lee HS, Bang HC. Detecting counterfeit products using supply chain event mining. InAdvanced Communication Technology (ICACT), 2013 15th International Conference on 2013 Jan 27 (pp. 744–748). IEEE.
114. Zikui L, Xuan G. The regulation model of pharmaceutical logistics based on the supervision of flow. InLogistics Systems and Intelligent Management, 2010 International Conference on 2010 Jan 9 (Vol. 2, pp. 1055–1059). IEEE.
115. Banerjee S, Sweet J, Sweet C, et al. Visual recognition of paper analytical device images for detection of falsified pharmaceuticals. InApplications of Computer Vision (WACV), 2016 IEEE Winter Conference on 2016 Mar 7 (pp. 1–9). IEEE.
116. NABP. VIPPS - national association of boards of pharmacy [Internet]. nabp.net. [cited 2011 Sep 21]. Available from:http://www.nabp.net/programs/accreditation/vipps/
117. EU logo for online sale of medicines [Internet]. ec.europa.eu. 2016 [cited 2016 Jan11]. Available from:http://ec.europa.eu/health/human-use/eu-logo/index_en.htm
118. LegitScript. Rogues and registrars:are some domain name registrars safe havens for internet drug rings? [Internet]. [cited 2014 Jun 17]. Available from:http://www.legitscript.com/download/Rogues-and-Registrars-Report.pdf
119. LegitScript. The-Internet-Pharmacy-Market-in-2016. Trends, Challenges and Opportunities. [Internet] [cited 2017 Mar 30]. Available from:https://safemedsonline.org/resource/the-internet-pharmacy-market-in-2016-trends-challenges-and-opportunities/
120. Mackey TK, Liang BA, Kohler JC, et al. Health domains for sale:the need for global health internet governance. J Med Internet Res. 2014;16(3):e62.
121. Mackey TK, Eysenbach G, Liang BA, et al. A call for a moratorium on the.health generic top-level domain:preventing the commercialization and exclusive control of online health information. Global Health. BioMed Central Ltd. 2014 Sep 26;10(1):62.
122. Solomonides AE, Mackey TK, Emerging ethical issues in digital health information. Camb Q Healthc Ethics. Cambridge University Press. 2015 Jul;24(3):311–322.
123. Home -.Pharmacy [Internet]. safe.pharmacy. 2017 [cited 2017 Jan30]. Available from:http://www.safe.pharmacy/
124. Norton S. CIO Explainer:what Is Blockchain? [Internet]. blogs.wsj.com. 2016 [cited 2017 Jan30]. Available from:http://blogs.wsj.com/cio/2016/02/02/cio-explainer-what-is-blockchain/
125. Mettler M. Blockchain technology in healthcare:the revolution starts here. Ine-Health Networking, Applications and Services (Healthcom), 2016 IEEE 18th International Conference on 2016 Sep 14 (pp. 1–3). IEEE.
126. Marr B. How blockchain technology could change the world [Internet]. forbes.com. 2016 [cited 2017 Jan30]. Available from:http://www.forbes.com/sites/bernardmarr/2016/05/27/how-blockchain-technology-could-change-the-world/
127. Harris P, Rubix by deloitte on blockchain use cases for the pharmaceutical supply Chain [Internet]. 2016 [cited 2017 Jan30]. Available from:/news/rubix-by-deloitte-on-blockchain-use-cases-for-the-pharmaceutical-supply-chain/
128. Shanley A, Could blockchain enable secure data transfer? [Internet]. 2016 [cited 2017 Jan30]. Available from:http://www.pharmtech.com/could-blockchain-enable-secure-data-transfer
129. Taylor P, Applying blockchain technology to medicine traceability [Internet]. 2016 [cited 2017 Jan30]. Available from:https://www.securingindustry.com/pharmaceuticals/applying-blockchain-technology-to-medicine-traceability/s40/a2766/
130. Holmes B, Blockchain Technology Battles Counterfeiting [Internet]. bravenewcoin.com. 2015 [cited 2017 Jan30]. Available from:http://bravenewcoin.com/news/blockchain-technology-battles-counterfeiting/
131. Allison I, Chronicled launches blockchain-registered supply chain and pharmaceutical packaging [Internet]. 2016 [cited 2017 Jan30]. Available from:http://www.ibtimes.co.uk/chronicled-launches-blockchain-registered-supply-chain-pharmaceutical-packaging-1592220
132. Del Castillo M, Hyperledger project explores fighting counterfeit drugs with blockchain [Internet]. 2016 [cited 2017 Jan30]. Available from:http://www.coindesk.com/hyperledger-counterfeit-drugs-blockchain/
133. IEEE Launches World’s First Virtual Blockchain Workshop Dedicated to Advancing HealthTech for Humanity [Internet]. standards.ieee.org. 2016 [cited 2017 Jan30]. Available from:http://standards.ieee.org/news/2016/virtual_blockchain.html
134. Blockchain for Pharma. Internet. 2017 [cited 2017 Jan30]. Available from:http://beyondstandards.ieee.org/tag/blockchain-for-pharma/
135. The BlockRx Project [Internet]. blockrx.com. 2016 [cited 2017 Jan30]. Available from:http://www.blockrx.com/
136. Zadbuke N, Shahi S, Gulecha B, et al. Recent trends and future of pharmaceutical packaging technology. J Pharm Bioallied Sci. 2013 Apr;5(2):98–110.
137. Jamrógiewicz M. Application of the near-infrared spectroscopy in the pharmaceutical technology. J Pharm Biomed Anal. 2012 Jul;66:1–10.
138. Culzoni MJ, Dwivedi P, Green MD, et al. Ambient mass spectrometry technologies for the detection of falsified drugs. Med Chem Commun. Royal Society of Chemistry. 2014;51:9–19.
139. Pal SN, Olsson S, Brown EG, The monitoring medicines project:a multinational pharmacovigilance and public health project. Drug Saf. Springer International Publishing. 2015 Apr;38(4):319–328.
140. Fukuoka T, Yamaguchi A, Hara R, et al. Application of gold nanoparticle self-assemblies to unclonable anti-counterfeiting technology. InElectronic Packaging and iMAPS All Asia Conference (ICEP-IACC), 2015 International Conference on 2015 Apr 14 (pp. 432–435). IEEE.
141. Das RN, Egitto FD, Lin H. Anti-counterfeit, miniaturized, and advanced electronic substrates for medical device applications. In Electronic Components and Technology Conference (ECTC), 2013 IEEE 63rd 2013 May 28 (pp. 523–528). IEEE.
142. Richards N, Hudson I. UK medicines regulation:responding to current challenges. Br J Clin Pharmacol. 2016 Dec;82(6):1471–1476.
143. Fayzrakhmanov NF. Fighting trafficking of falsified and substandard medicinal products in Russia. Int J Risk Saf Med. IOS Press. 2015;27Suppl 1(s1):S37–40.